Here’s What the Street is Saying About Eli Lilly and Company (LLY)

Eli Lilly and Company (NYSE:LLY) is one of the best medical stocks to invest in according to billionaires. Eli Lilly and Company (NYSE:LLY) received a rating update from Truist on May 1, with the firm maintaining a Buy rating on the shares with a price target of $1,281. It stated that the company’s retatrutide Phase 3 clinical trial data in obesity announced the same day marks a new benchmark for anti-obesity medications, showing that patients on retatrutide high dose of 12 mg saw 28.3% weight loss at 80 weeks and 30.3% at 104 weeks. The firm told investors in a research note that it believes this will support retatrutide approval and use in patients that are not adequately served with existing incretin options.

CNBC Reports Strong Phase 3 Results for Eli Lilly’s Retatrutide

The same day, Wolfe Research also maintained an Outperform rating on Eli Lilly and Company with a price target of $1,350. It told investors in a research note that the company’s reported pivotal phase 3 results for retatrutide further bolster its GLP-1 franchise leadership and differentiation in obesity therapeutics.

Eli Lilly and Company develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Follow Insider Monkey on Google News.